The 5th US Circuit barred mailing mifepristone nationwide and required in-person dispensing, citing the FDA's still-unfinished safety review.
The ruling is expected to be appealed to the Supreme Court and could disrupt abortion and miscarriage care, especially for patients relying on telehealth and mail delivery.
The case is part of broader Republican-led state challenges to FDA abortion-pill rules; medication abortions account for nearly two-thirds of US pregnancy terminations.
How could a ruling on one pill reshape the future of telehealth and all FDA-approved medicines?
With mailed prescriptions blocked, what new hurdles will patients in remote areas face for essential healthcare?
Louisiana v. FDA: How a 2026 Ruling Threatens Telehealth Abortion Access Across the United States
Overview
In April 2026, the conservative 5th Circuit Court of Appeals ruled to block the FDA's 2023 rule allowing mail and telehealth access to the abortion drug mifepristone, reinstating in-person requirements nationwide. This ruling, driven by Louisiana's lawsuit challenging the FDA's authority, immediately restricted medication abortion access, especially in states with abortion bans, and intensified legal conflicts between states. The FDA's earlier approvals and expansions were based on strong scientific evidence, but the ruling contradicts this and forces some providers to use less effective methods with harsher side effects. The case is now being appealed to the Supreme Court, with medical groups warning that upholding the ruling could politicize medicine and destabilize drug regulation.